Sustained response to low‐dose rituximab in idiopathic autoimmune hemolytic anemia
Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Alberto Zanella(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Francesco Zaja, Dario Consonni(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Agostino Cortelezzi(University of Milan), Bruno Fattizzo(University of Milan), Anna Zaninoni(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Eros Di Bona(San Antonio College), Francesca Guia Imperiali(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Cited by 63
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|371